About 400 reports

  • Diagnosis of lymphoma
  • Tests for lymphoma

About Lymphoma Drugs Lymphoma is a type of cancer that affects the immune system of the body. Specifically, it affects the lymphocytes, a type of white blood cell. The lymphocytes are part of the immune system and help the body to fight infections. The cancerous lymphocytes grow uncontrollably and collect in different portions...

  • Lymphoma
  • United States
  • Celgene Corporation
  • Seattle Genetics, Inc.
  • Takeda Pharmaceutical Company Limited
  • Lymphoma Treatment Drugs Imports and Exports
  • IV. LYMPHOMA TREATMENT DRUGS PRODUCTION AND

China’s demand for Lymphoma Treatment Drugs has grown at a fast pace in the past decade. In the next decade, both production and demand will continue to grow. The Chinese economy maintains a high speed growth which has been stimulated by the consecutive increases of industrial output, imports & exports, consumer consumption...

  • Lymphoma
  • China
  • Beijing Wintic Pharma Co., Ltd
  • Shandong Luoxin Pharmacy Stock Co., Ltd.
  • Zhejiang Hisun Pharmaceutical Co., Ltd.
  • Lymphoma Treatment Drugs Exports
  • Other Lymphoma Treatment Drugs

This study focuses on China’s Lymphoma Treatment Drugs industry forecasts. In the two past decades, the industry has been growing at a fast pace. The dramatic expansions of the manufacturing capabilities and rising consumer consumptions in China have transformed China’s society and economy. China is one of the world’s major...

  • Lymphoma
  • China
  • Demand
  • Pfizer Inc.
  • Zhejiang Hisun Pharmaceutical Co., Ltd.
  • III. LYMPHOMA
  • Lymphoma Treatment Drugs Industry Structure

This study focuses on China’s Lymphoma Treatment Drugs industry assessments and company profiles. In the two past decades, the industry has been growing at a fast pace. The dramatic expansions of the manufacturing capabilities and rising consumer consumptions in China have transformed China’s society and economy. China is one...

  • Lymphoma
  • China
  • Beijing Wintic Pharma Co., Ltd
  • Ltd Jiangsu Hengrui Medicine Co.
  • Ltd Shenzhen Main Luck Pharmaceuticals Inc.

The 2019-2024 World Outlook for Lymphoma Therapeutics ## INTRODUCTION ##. ## OVERVIEW ##. ## WHAT IS LATENT DEMAND AND THE P. I. E.?

  • Cancer
  • Lymphoma
  • World
  • Demand

Global Diffuse Large B Cell Lymphoma Drug Market, Dosage, Price & Clinical Pipeline Outlook 2024 ##.

  • Cancer
  • Lymphoma
  • Therapy
  • World
  • Market Size
  • Ann Arbor staging used in lymphoma
  • Marketed Drugs: Diffuse Large B-Cell Lymphoma

An increase in disease prevalence and the launch of new targeted therapies across a range of treatment settings will drive the growth of the diffuse large B-cell lymphoma (DLBCL) market during 2016–25 despite Rituxan’s patent expiry. This report addresses the following questions: - What will drive the growth of the DLBCL...

  • Lymphoma
  • European Union
  • Japan
  • United States
  • Roche Group
  • Marketed Drugs: Follicular Lymphoma
  • Pipeline: Follicular Lymphoma

The follicular lymphoma (FL) market will continue to grow during 2016–25, despite the entry of biosimilars and generics, due to an increase in disease incidence and the launch of new pipeline therapies. This report addresses the following questions: - What will be driving the growth of the FL market during 2016–25? -...

  • Lymphoma
  • European Union
  • Japan
  • North America
  • United States
  • Epidemiology: Mantle Cell Lymphoma
  • TREATMENT: MANTLE CELL LYMPHOMA

An increase in incident cases, combined with the expanded use of costly treatments such as Imbruvica and Revlimid, will drive the growth of the mantle cell lymphoma (MCL) market during 2016–25. This report addresses the following questions: - What will be driving the growth of the MCL market during 2016–25? - Which markets...

  • Lymphoma
  • European Union
  • United States
  • Celgene Corporation
  • Roche Group

Indolent Lymphoma - Epidemiology Forecast to 2027 ##.

  • Lymphoma
  • France
  • Germany
  • Italy
  • Spain

Small lymphocytic lymphoma -Epidemiology Forecast to 2027 ##.

  • Lymphoma
  • France
  • Germany
  • Italy
  • Spain

B-Cell Lymphomas - Epidemiology Forecast to 2027 ##.

  • Lymphoma
  • France
  • Germany
  • Italy
  • Spain

Drug A: Company ## ##. ##. ##.

  • Cancer
  • Lymphoma
  • United States
  • Market Shares

Drug A: Company ## ##. ##. ##.

  • Cancer
  • Lymphoma
  • United States
  • Market Shares

Drug A: Company ## ##. ##. ##.

  • Cancer
  • Lymphoma
  • United States
  • Market Shares
  • 9.27 Lymphoma, Hodgkin's - Market & Forecast
  • 10.28 Lymphoma, Non-hodgkin's - Patient Numbers & Forecast

Rising incidences of Pediatric cancer has provoked medical organizations towards development and implementation of sophisticated treatment procedures, which is “Proton Radiotherapy”. The efficiency of proton therapy continues to add trust of Pediatric cancer patients globally. The course of action is known for successfully destructing tumor...

  • Lymphoma
  • North America
  • United States
  • Forecast
  • Market Size
  • 3.5.1 Follicular Lymphoma
  • 3.5.2 Marginal Zone Lymphoma

EpiCast Report: Non-Hodgkin’s Lymphoma - Epidemiology Forecast to 2024 Summary Non-Hodgkin’s Lymphoma (NHL) refers to a group of cancers that develop in the lymphatic system. In NHL, the body’s immune system is affected by the uncontrollable growth of malignant white blood cells, resulting in the body’s inability to fight...

  • Lymphoma
  • Japan
  • United States
  • World
  • Forecast
  • LYMPHOMA MARKET BY DRUG TYPE ($ MILLIONS)
  • Chapter 9: Pipeline Disruptors: Lymphoma

This report covers market opportunities based on pipeline developments for six key therapeutic specialities: Alzheimer's Disease Asthma Breast Cancer Leukemia Lung Cancer Lymphoma These six areas are expected to show the strongest pipeline impact and candidates are likely to replace current therapies. The...

  • Lymphoma
  • AstraZeneca PLC
  • Novartis AG
  • Pfizer Inc.
  • Roche Group

Global Non-Hodgkins Lymphoma Epidemiology and Patient Flow Analysis - 2017 ##.

  • Lymphoma
  • France
  • United States
  • World
  • Forecast
  • LYMPHOMA (CHL)
  • COMBINATION REGIMENS FOR DIFFERENT TYPES OF LYMPHOMAS

“Adcetris: 2011-2015 analysis; 2016-2021 expectations” is a comprehensive report on the first and only approved drug of Seattle Genetics called Adcetris, which is also the first drug approved by the USFDA for classical Hodgkin’s Lymphoma (cHL) in 34 years (1977-2011). It was launched in 2011 in the US for Hodgkin’s lymphoma and systemic anaplastic...

  • Lymphoma
  • North America
  • United States
  • Seattle Genetics, Inc.
  • Takeda Pharmaceutical Company Limited
  • ENDPOINT RESULTS FOR DRUGS IN SMALL LYMPHOCYTIC LYMPHOMA
  • DRUG FORRELAPSED SMALL LYMPHOCYTIC LYMPHOMA TREATMENT

Zydelig (idelalsib): strong start but not expected to continue” is a comprehensive report on the first-in-class, targeted, oral PI3K delta inhibitor approved drug for relapsed chronic lymphocytic leukemia (CLL), relapsed follicular B-cell non-Hodgkin’s lymphoma (FL) and relapsed small lymphocytic lymphoma (SLL). Zydelig falls under...

  • Leukemia
  • Lymphoma
  • United States
  • Gilead Sciences, Inc.
  • Roche Group
  • ENDPOINT RESULTS FOR DRUGS IN MANTLE CELL LYMPHOMA
  • Efficacy endpoint: Relapsed mantle cell lymphoma study

Description “Oncology drug report - Revlimid - lenalidomide - 2005-2015 analysis; 2016-2021 expectations” is a comprehensive drug report on the fouth-largest oncology drug by 2015 sales. Revlimid is the largest drug in Celgene’s portfolio and falls in targeted therapy, under the im-munomodulator class of drugs. It is indicated...

  • Lymphoma
  • Targeted Therapy
  • United States
  • Demand
  • Celgene Corporation
  • 6.27 Lymphoma, Hodgkin's - Market & Forecast
  • 7.28 Lymphoma, Non-hodgkin's - Patient Numbers & Forecast

By the year 2021, United State Pediatric Proton Therapy Market has the potential to reach close to US$ 350 Million. However, According to this report, the actual market is anticipated to be less than half of the potential figure, due to Demand and Supply divergence in the United State. The Pediatric cancer cases in the USA are rising rapidly...

  • Lymphoma
  • North America
  • United States
  • Forecast
  • Mitsubishi Corporation

This influence varies from one industry to another, but also from one period of time to another.

  • Cancer
  • Lymphoma
  • Therapy
  • World
  • Demand
  • Incidence of Burkitt's Lymphoma, (000s)
  • B-CELL LYMPHOMAS

Black Swan Analysis Epiomic™ Epidemiology Series Forecast Report on Non-Hodgkin Lymphoma in 18 Major Markets Non-Hodgkin Lymphomas (NHL) are a diverse group of blood cancers that develop from lymphocytes (a type of white blood cell). As the name suggests, they include all lymphomas except Hodgkin’s lymphoma. There are about 35 different...

  • Cancer
  • Lymphoma
  • North America
  • Forecast
  • Market Size

(% market share) CHAPTER ##: PIPELINE DISRUPTORS: LYMPHOMA MARKET OPPORTUNITY Non-Hodgkin' s Lymphoma Table ##-##: Classification of Non-Hodgkin' s Lymphomas Hodgkin' s Lymphoma Figure ##-##: Global Incidence and Mortality of Lymphoma by Country, ##

  • Leukemia
  • Lymphoma
  • Oncology
  • World
  • Market Size

Hodgkin Lymphoma Phase ## Clinical Trials, 2016 ##.

  • Lymphoma
  • France
  • United States
  • Market Shares
  • Market Size

Non-Hodgkin Lymphoma Phase ## Clinical Trials, 2016 ##.

  • Lymphoma
  • France
  • United States
  • Market Shares
  • Market Size

The majority of the pipeline drugs in development are administered via the oral and intravenous route, with one product being tested in intratumoral formulation.

  • Cancer
  • Lymphoma
  • United States
  • World
  • Market Description
  • LYMPHOMA
  • LYMPHOMA

INTRODUCTION Since the first approval of MYLOTARG™ in 2000 and its subsequent withdrawal in the year 2010, the ADC market has evolved considerably. In the last seven years, the market has witnessed an increasing interest from drug developers and healthcare investors alike. Post the commercialization of ADCETRIS®...

  • Lymphoma
  • North America
  • United States
  • Market Size
  • Seattle Genetics, Inc.